Identification of pharmacological inhibitors of the MEK5/ERK5 pathway

被引：132

作者：

Tatake, Revati J. ^{[1
]}

O'Neill, Margaret M. ^{[1
]}

Kennedy, Charles A. ^{[1
]}

Wayne, Anita L. ^{[1
]}

Jakes, Scott ^{[1
]}

Wu, Di ^{[2
]}

Kugler, Stanley Z., Jr. ^{[2
]}

Kashem, Mohammed A. ^{[2
]}

Kaplita, Paul ^{[3
]}

Snow, Roger J. ^{[2
]}

机构：

[1] Boehringer Ingelheim Pharmaceut Inc, Dept Cardiovasc Dis, Ridgefield, CT 06877 USA

[2] Boehringer Ingelheim Pharmaceut Inc, Dept Med Chem, Ridgefield, CT 06877 USA

[3] Boehringer Ingelheim Pharmaceut Inc, Dept Drug Discovery Support, Ridgefield, CT 06877 USA

来源：

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | 2008年 / 377卷 / 01期

关键词：

MEK5; ERK5; Kinase inhibitors; Pharmacological inhibitors;

D O I：

10.1016/j.bbrc.2008.09.087

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

We have identified two novel MEK5 inhibitors, BIX02188 and BIX02189, which inhibited catalytic function of purified, MEK5 enzyme. The MEK5 inhibitors blocked phosphorylation of ERK5, without affecting phosphorylation of ERK1/2 in sorbitol-stimulated HeLa cells. The compounds also inhibited transcriptional activation of MEF2C, a downstream substrate of the MEK5/ERK5 signaling cascade, in a cellular trans-reporter assay system. These inhibitors offer novel pharmacological tools to better characterize the role of the MEK5/ERK5 pathway in various biological systems. (C) 2008 Elsevier Inc. All rights reserved.

引用

页码：120 / 125

页数：6

共 50 条

[41] Dual inhibition of the PI3k/Akt and MEK5/ERK5 pathways in tamoxifen resistant breast cancer
Wright, Thomas D.
Hasan, Mahmud
Witt-Enderby, Paula
Cavanaugh, Jane
CANCER RESEARCH, 2017, 77
[42] The MEK5/ERK5 mitogen-activated protein kinase cascade is an effector pathway of bone-sustaining bisphosphonates that regulates osteogenic differentiation and mineralization
Adam, Christian
Glueck, Lucia
Ebert, Regina
Goebeler, Matthias
Jakob, Franz
Schmidt, Marc
BONE, 2018, 111 : 49 - 58
[43] Impairment of ERK5 Nuclear Localization Restores Sensitivity to ERK5 Kinase Inhibitors
Lombardi, Z.
Gardini, L.
Menconi, A.
Tusa, I.
Lulli, M.
Rovida, E.
JOURNAL OF MOLECULAR DIAGNOSTICS, 2023, 25 (06): : S63 - S64
[44] Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway
Mody, N
Leitch, J
Armstrong, C
Dixon, J
Cohen, P
FEBS LETTERS, 2001, 502 (1-2) : 21 - 24
[45] PB1 domains of MEKK2 and MEKK3 interact with the MEK5 PB1 domain for activation of the ERK5 pathway
Nakamura, K
Johnson, GL
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (39) : 36989 - 36992
[46] Evaluation of synergistic PI3K/Akt and MEK5/ERK5 inhibition in triple-negative breast cancer
Wright, Thomas D.
Raybuck, Christopher
Gartland, Nathan
Wendekier, Katy
Monlish, Darlene
Chakrabarty, Suravi
Flaherty, Patrick T.
Burow, Matthew E.
Cavanaugh, Jane E.
CANCER RESEARCH, 2018, 78 (13)
[47] Induction of smooth muscle α-actin by arginine vasopressin in vascular smooth muscle cells is regulated by p38 map kinase and the MEK5/ERK5 pathway
Nemenoff, RA
Kaplan-Albuquerque, N
Garat, C
CIRCULATION, 2000, 102 (18) : 325 - 325
[48] LOCALIZATION OF THE MITOGEN-ACTIVATED PROTEIN-KINASE ERK5 AND ITS UPSTREAM ACTIVATOR MEK5 IN RAT-BRAIN
CHAO, HHJ
KWAK, SP
DIXON, JE
MOLECULAR BIOLOGY OF THE CELL, 1995, 6 : 736 - 736
[49] Optimization of quinazoline derivatives as selective MEK5 inhibitors
Patel, Saloni
Motta, Austin
Flaherty, Patrick
Bhatt, Akshita
Wright, Thomas
Cavanaugh, Jane
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
[50] Activation of the MEK5/ERK5 cascade in biliary epithelium of polycystic kidney rat, an animal model of Caroli's disease.
Sato, Y
Harada, K
Nakanuma, Y
HEPATOLOGY, 2003, 38 (04) : 679A - 679A

← 1 2 3 4 5 →